ArticleNature medicine2025

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.

Yago Nieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.